Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating on October 13.
David Risinger’s rating of Sanofi’s stock as a ‘Buy’ is grounded in several factors. Primarily, the efficacy data from 24 weeks of Amlitelimab (anti-OX40L) showed considerable improvement from the 16-week data. The safety profile of the drug is deemed particularly appealing, particularly as it doesn’t report fever-like adverse events, unlike AMGN’s OX40 rocatinlimab. Risinger also commends the deepening of Amlitelimab’s responses over time, which appear to be on par with competing agents by week 24.
In addition, Risinger sees potential in Sanofi testing higher doses of Amlitelimab in the planned Phase 3, which could support longer dosing intervals than the Phase 2b trial’s every 4 weeks dosing. The analyst also highlights that the Phase 2b trial will follow patients through 52 weeks and re-randomise responders to placebo or their existing dose of Amlitelimab. This, coupled with future results from the withdrawal / placebo arm, could provide informative insights into the drug’s durability of effect and dosing interval. The upcoming commentary from Sanofi’s management on Amlitelimab’s development program is also eagerly anticipated by Risinger.
According to TipRanks, Risinger is a 5-star analyst with an average return of 11.0% and a 58.22% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Amgen, Halozyme, and Pfizer.
In another report released on October 13, Bank of America Securities also maintained a Buy rating on the stock with a $72.00 price target.
See the top stocks recommended by analysts >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Sanofi (SNYNF) Company Description:
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Human Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes & cardiovascular, established prescription products and generics, together with research, development and production activities. This segment also includes all associates whose activities are related to pharmaceuticals. The Consumer Healthcare segment comprises, for all geographical territories, the commercial operations for its Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development and production activities dedicated to vaccines. The company was founded in 1973 and is headquartered in Paris, France.
Read More on SNYNF:
- Sanofi says amlitelimab Phase 2b data show ‘potential best-in-class’ AD profile
- Negative Amgen AdCom a positive for Mirati, says Jefferies
- Mirati Therapeutics price target raised to $72 from $31 at BMO Capital
- Tango Therapeutics rises after report of Mirati takeover interest
- Mirati continues advance, up 30% after Bloomberg reports Sanofi buyout interest
